British drugmaker GSK (LSE: GSK) has presented positive results from the Phase III EAGLE-2 and EAGLE-3 studies of gepotidacin.
GSK is testing the first-in-class oral antibiotic for the treatment of uncomplicated urinary tract infections in female adults and adolescents.
With a lack of investment in the antibiotic space, concerns about antimicrobial resistance have gone hand-in-hand with a general paucity of novel options for people with regular infections.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze